Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001219034 | SCV001390954 | pathogenic | Renal carnitine transport defect | 2023-09-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC22A5 protein function. ClinVar contains an entry for this variant (Variation ID: 947886). This missense change has been observed in individual(s) with clinical features of SLC22A5-related conditions (PMID: 35095998; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs759925126, gnomAD 0.0009%). This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 157 of the SLC22A5 protein (p.Ser157Phe). |
Mayo Clinic Laboratories, |
RCV004792811 | SCV005411862 | uncertain significance | not provided | 2023-09-12 | criteria provided, single submitter | clinical testing | PP3, PM2, PM3_supporting |
Natera, |
RCV002226520 | SCV002078305 | uncertain significance | Decreased circulating carnitine concentration | 2020-07-06 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001219034 | SCV002107429 | uncertain significance | Renal carnitine transport defect | 2020-07-06 | no assertion criteria provided | clinical testing |